EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Graves’ Disease before and after the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: Experience of a Clinical Center

Juliana Marques Sá, Ana Sofia Correia, Maria Joana Santos

Endocrinology Insights · 2025

DOI: 10.1159/000545071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology Insights, 2025. Verfasst von Juliana Marques Sá und 2 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

New cases of Graves’ disease (GD) have been reported in association with SARS-CoV-2 infection and vaccination. We aimed to determine if there was an increase in the new cases of GD after the SARS-CoV-2 pandemic, to compare the characteristics of GD patients before and after the pandemic, and to compare GD patients’ characteristics in relation to the presence of SARS-CoV-2 infection and/or vaccination.

Methods

Retrospective and observational study evaluating sociodemographic, analytical, and treatment-related characteristics of newly diagnosed GD patients, who had their first consultation at the Endocrinology Department of Hospital de Braga between 2018 and 2022 (GDbP: pre-pandemic symptoms; GDaP: post-pandemic symptoms). GDaP was subdivided into four subgroups (GDnIV, GDwI, GDwV, and GDwIV) based on SARS-CoV-2 infection (I) and/or vaccination (V).

Results

We included 250 patients: 108 (43.2%) in the GDbP group and 142 (56.8%) in the GDaP group. There was a significant increase in the first endocrinology appointments due to GD after the pandemic (2.85% vs 5.11%, p < 0.001). When compared to GDbP, GDaP took less time to start (p < 0.05), reduce dosage (p < 0.05), and discontinue medical treatment (p < 0.05). Compared to the GDbP group, the GDwI subgroup showed higher anti-Tg levels (p < 0.05); the GDnIV, GDwV, and GDwIV subgroups took less time to initiate and discontinue medical treatment (p < 0.05). GDwI and GDwV patients had higher free thyroxine (FT4) levels than the GDnIV group (p < 0.05). GDwV patients took less time to reduce medical treatment dose compared to GDnIV (p < 0.05).

Conclusions

There was an increase in the number of new GD cases with the SARS-CoV-2 pandemic. These patients took less time to initiate, reduce, and discontinue medical treatment. Some subgroups with GD related to I and V showed higher FT4 and anti-Tg titers when compared to pre-pandemic GD patients or GD with no relation to SARS-CoV-2 infection or vaccination.

Zitieren

APA

Sá, J. M., Correia, A. S., & Santos, M. J. (2025). Graves’ Disease before and after the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: Experience of a Clinical Center. Endocrinology Insights. https://doi.org/10.1159/000545071

Vancouver

Sá JM, Correia AS, Santos MJ. Graves’ Disease before and after the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: Experience of a Clinical Center. Endocrinology Insights. 2025. doi:10.1159/000545071

BibTeX
@article{S2025,
  author = {Sá, Juliana Marques and Correia, Ana Sofia and Santos, Maria Joana},
  title = {Graves’ Disease before and after the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: Experience of a Clinical Center},
  journal = {Endocrinology Insights},
  year = {2025},
  doi = {10.1159/000545071}
}
Kostenlos starten →